Editas Medicine Inc (NASDAQ:EDIT)’s traded shares stood at 1.22 million during the last session, with the company’s beta value hitting 1.95. At the close of trading, the stock’s price was $2.96, to imply a decrease of -3.58% or -$0.11 in intraday trading. The EDIT share’s 52-week high remains $11.69, putting it -294.93% down since that peak but still an impressive 8.78% since price per share fell to its 52-week low of $2.70. The company has a valuation of $244.34M, with an average of 2.34 million shares in intraday trading volume over the past 10 days and average of 1.96 million shares over the past 3 months.

Analysts have given a consensus recommendation of Buy for Editas Medicine Inc (EDIT), translating to a mean rating of 2.00. Of 9 analyst(s) looking at the stock, 0 analyst(s) give EDIT a Sell rating. 0 of those analysts rate the stock as Overweight while 3 advise Hold as 6 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.4.

Editas Medicine Inc (NASDAQ:EDIT) trade information

After registering a -3.58% downside in the last session, Editas Medicine Inc (EDIT) has traded red over the past five days. The 5-day price performance for the stock is -9.76%, and -11.90% over 30 days. With these gigs, the year-to-date price performance is -70.78%. Short interest in Editas Medicine Inc (NASDAQ:EDIT) saw shorts transact 17.24 million shares and set a 8.76 days time to cover.

The extremes give us $5 and $35 for target low and target high price respectively. As such, EDIT has been trading -1082.43% off suggested target high and -68.92% from its likely low.

Editas Medicine Inc (EDIT) estimates and forecasts

Looking at statistics comparing Editas Medicine Inc share performance against respective industry, we note that the company has underperformed competitors. Editas Medicine Inc (EDIT) shares are -50.67% down over the last 6 months, with its year-to-date growth rate lower than industry average at -35.15% against 17.10%. Revenue is forecast to shrink -74.42% this quarter before jumping 6.32% for the next one. The rating firms project that company’s revenue will shrink -48.12% compared to the previous financial year.

Revenue forecast for the current quarter as set by 16 analysts is 33.02M. Meanwhile, for the current quarter, a total of 8 analyst(s) estimate revenue growth to 2.52M.Earnings reports from the last fiscal year show that sales brought in 60.05M and 1.14M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -45.02% before jumping 122.04% in the following quarter.

An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 2.88% for the past 5-year period. While 2024 is set for a -32.75% return in earnings, projections for the next 5 years are at 1.70% annually.

EDIT Dividends

Editas Medicine Inc has its next earnings report out in December. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.

Editas Medicine Inc (NASDAQ:EDIT)’s Major holders

Editas Medicine Inc insiders hold 0.32% of total outstanding shares, with institutional holders owning 66.07% of the shares at 66.29% float percentage. In total, 66.07% institutions holds shares in the company, led by VANGUARD GROUP INC. As of 2024-06-30, the company held over 8.03 million shares (or 9.8032% of shares), all amounting to roughly $37.51 million.

The next major institution holding the largest number of shares is BLACKROCK INC. with 7.78 million shares, or about 9.498% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $36.34 million.